Phase II study of S-1 in patients with gemcitabine-resistant advanced pancreatic cancer

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

Howard A. Burris, Malcolm J. Moore, John Sahl Andersen et al. · Journal of Clinical Oncology · 1997 · 5.9K citations

Medicine, Oncology, Pharmacotherapy +16

Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators

Tetsuhiko Shirasaka, Yuji Shimamato, Hideyuki Ohshimo et al. · Anti-Cancer Drugs · 1996 · 824 citations

Medicine, Medicinal Chemistry, Pharmacology +16

Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1M tegafur–0.4M gimestat–1M otastat potassium) in advanced gastric cancer patients

Yuh Sakata, Atsushi Ohtsu, N Horikoshi et al. · European Journal of Cancer · 1998 · 564 citations

Medicine, Oncology, Pharmacology +11

Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats.

Tetsuhiko Shirasaka, Yuji Shimamoto, Masakazu Fukushima · PubMed · 1993 · 350 citations

Medicine, Pharmacology, Toxicology +11

Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts.

Kunihiko Tatsumi, Masakazu Fukushima, Tetsuhiko Shirasaka et al. · PubMed · 1987 · 261 citations

Life Sciences, Biochemistry, Pharmacology +10